Naslov
HCV life cycle-source of a new DAA

Autori
Wagner, Jasenka

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Program and abstracts, 1st International Monothematic Conference on Viral Hepatitis C (IMC-HCV-2014), September 11-13, Opatija, Croatia / M. Smolić, A. Včev, George Y. Wu - Osijek : Medicinski fakultet Sveučilišta Josipa Jurja Strossmayera u Osijeku, 2014, 42-43

ISBN
978-953-7736-20-0

Skup
1st International Monothematic Conference on Viral Hepatitis C (IMC-HCV-2014), September 11-13, Opatija, Croatia

Mjesto i datum
Opatija, Hrvatska, 11.09.2014. - 13.09.2014

Vrsta sudjelovanja
Pozvano predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
HCV; DAA

Sažetak
Hepatitis C Virus (HCV) is a positive-sense, single-stranded enveloped RNA virus approximately 9600 nucleotides in length. It belongs in the Flaviviridae family. Due to the highly error prone RNA polymerase, HCV displays remarkable genetic diversity and propensity for selection of immune evasion or drug resistance mutations. Recent HCV therapeutic development has been greatly enhanced by basic understanding of HCV virology and life cycle, through studies using HCV cell culture systems and replication assays. Since progress in understanding HCV biology has been trigger for creating a remarkably rich pipeline of direct acting antiviral compounds (DAA) in various stages of preclinical and clinical developments (phases 2 or 3 of clinical trials), this lecture will give brief overview of different viral and host cellular factors interacting in HCV life cycle steps such as viral attachment, entry, and fusion ; HCV RNA translation ; posttranslational modification ; HCV replication ; virus assembly and release. Investigated DAAs act as either NS3-NS4A protease inhibitors which interact with translation and polyprotein processing or as NS5A inhibitors or NS5B polymerase inhibitors which interact with HCV RNA replication or assembly and virion morphogenesis. At the moment, there is a large number of IFN-free clinical studies combining one, two or three antiviral agents, with or without ribavirin. However, severe side effects, resistance and drug-drug interactions are still issues, so the search for the holy grail of HCV treatment, an all-oral highly effective IFN free regimen, continues.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti

POVEZANOST RADA